Man Group’s Palvella Therapeutics PVLA Stock Holding History

Man Group’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-866	Closed	-$158K	–	1865
2022 Q1	$210K	Buy	+866	New	+$228K	﹤0.01%	1921
2021 Q1	–	Sell	-470	Closed	-$94K	–	2023
2020 Q4	$94K	Hold	470	–	–	﹤0.01%	1778
2020 Q3	$78K	Sell	470 -5	-1%	-$1.14K	﹤0.01%	1749
2020 Q2	$118K	Hold	475	–	–	﹤0.01%	1625
2020 Q1	$87K	Sell	475 -49	-9%	-$12.3K	﹤0.01%	1528
2019 Q4	$152K	Buy	+524	New	+$145K	﹤0.01%	1780
2019 Q2	–	Sell	-190	Closed	-$51K	–	2025
2019 Q1	$51K	Hold	190	–	–	﹤0.01%	1934
2018 Q4	$40K	Buy	190 +7	+4%	+$2.17K	﹤0.01%	1882
2018 Q3	$82K	Sell	183 -38	-17%	-$16.5K	﹤0.01%	2055
2018 Q2	$90K	Buy	221 +6	+3%	+$2.85K	﹤0.01%	2075
2018 Q1	$117K	Buy	+215	New	+$133K	﹤0.01%	1955

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Man Group's PVLA Position: Q2 2022 in Review

Man Group sold out of Palvella Therapeutics (PVLA) in Q2 2022, closing a stake of 866 shares — an estimated $158K sold.

Man Group first reported a position in PVLA in Q1 2018 and held it in 11 quarters. The position peaked at $210K in Q1 2022. 68 funds tracked by Wall St. Rank hold PVLA as of Q2 2022.

Man Group reported no remaining Palvella Therapeutics position as of Q2 2022 after selling out during the quarter.
Man Group sold 866 Palvella Therapeutics shares in Q2 2022, an estimated $158K.
Man Group first reported a position in Palvella Therapeutics in Q1 2018 and held it in 11 quarters.
Man Group's Palvella Therapeutics position peaked at $210K in Q1 2022.
68 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.